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92Hypertension and dyslipidemia belong to the most prevalent modifiable risk factors for cerebrovascular and cardiovascular dis-
eases. Hereby, we aimed to examine the combined effects of newly diagnosed hypertension and hyperlipidemia on the char-
acteristics of the arterial wall and on cognitive function. We examined 72 hypertensive and 85 apparently healthy individuals.
Based on serum lipid levels, four subgroups were created ranging from normotensive-normolipidemic to hypertensive-
hyperlipidemic subjects. Carotid intima-media thickness (IMT), arterial stiffness, and cognitive function were assessed.
IMT of controls was the lowest, whereas that of patients with both risk factors the highest. Stiffness parameters increased
when both risk factors were present, whereas subjects with only one risk factor exhibited intermediate values. Hypertensive
patients performed worse when memory, attention, reaction time, and trait anxiety were assessed. Significant worsening of
IMT, arterial stiffness, and sum of neuropsychological scores was observed along with increasing mean arterial pressure.
Generally, hyperlipidemia combining with hypertension resulted in further worsening of all examined parameters. Subclinical
changes of the vascular wall and cognitive performance are already present in recently diagnosed hypertensive patients. Com-
bination of hyperlipidemia and hypertension results in more severe impairments, therefore, early and intensive treatment may
be crucial to prevent further deterioration. JAm Soc Hypertens 2014;-(-):1–11. 2014 American Society of Hypertension.
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Hypertension is one of the most important modifiable risk
factors for cerebrovascular diseases resulting in severe target
organ damage. The risk of cardiovascular diseases increases
continuously as blood pressure (BP) rises from levels that
are considered to be within the normal range.1 Based on pre-
vious observations, the higher the BP, the greater the risk of
stroke, and this correlation can be applied in the nonhyper-
tensive range as well.2 In addition, hypertension has also
been implicated in the development of impaired cognitiveion. All rights reserved.
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199function. Clinical trials and observational studies showed
that lowering BP to <140/90 mm Hg decreases morbidity
and mortality, although it improves quality of life by preser-
ving cognitive function. One of the greatest benefits of hy-
pertension control is the reduction of stroke risk, which is
the strongest contributor to dementia and cognitive function
decline.3 Besides the possible neuropsychological deteriora-
tion caused by hypertension, other feared complications of
long-lasting high BP are also well known. Although major
clinical events such as stroke or heart attack usually happen
after long periods of uncontrolled hypertension, subtle target
organ damage such as left ventricular hypertrophy, microal-
buminuria, or milder cognitive dysfunction takes place early
in the course of hypertension.4
Hypercholesterolemia is also a highly prevalent,modifiable
risk factor for vascular diseases. Elevated low-density lipopro-
tein cholesterol (LDL–C) is central to the development and
progression of atherosclerosis.5 Without any clinical symp-
toms, atherosclerosis can already be in an advanced stage in
hyperlipidemic patients.6 Large, population-based studies
demonstrated previously that hyperlipidemia, particularly
hypercholesterolemia, is associated with the risk of subse-
quent occurrence of mild cognitive impairment, particularly
in middle age.7–9 High cholesterol is often a prerequisite for
atherosclerotic plaque formation.10 Consequently, atheroscle-
rosis and dyslipidemia have become primary targets of inter-
vention in strategies for preventing vascular events.11,12
In the present study, we examined the combined effect of
hypertension and elevated LDL–C level on the morphologic
and functional properties of the arterial wall, represented by
intima-media thickness (IMT) and arterial stiffness parame-
ters, respectively. The influence of the two risk factors on
cognitive function was also evaluated. Our aims were to (1)
detect early changes in the morphologic and functional pa-
rameters of the arterial wall caused by early-stage hyperten-
sion, (2) analyzewhether these changes aremore pronounced
when hypertension is combined with hyperlipidemia, and (3)















215Ninety-four recently diagnosed hypertensive patients were
screened during the study period. From the initial database, 16
patients were excluded because of diabetes, chronic diseases,
or lack of compliance. To guard against the confounding
effects of possible long-standing, asymptomaticBP elevation,
6 patients were further excluded from the study, in whom
explicit target organ damage could be identified by urine
analysis (microalbuminuria or macroalbuminuria), echocar-
diography (left ventricular hypertrophy), cerebral compu-
ted tomography (silent brain infarction), or fundoscopic
examination (advanced retinopathy). Finally, 72 recentlyFLA 5.2.0 DTD  JASH508_proof diagnosed hypertensive patients (mean age  standard error
of the mean [SEM], 43.60  1.20 years; male/female ratio,
0.95) were recruited in the study cohort. The control group
consisted of 85 apparently healthy individuals (mean
age  SEM, 43.56  0.97 years; male/female ratio, 1.13).
The study was approved by the local Ethical Committee of
the University of Debrecen. Informed consent was obtained
from all patients and controls.
Based on the serum LDL–C level (higher or lower than
3.4 mmol/L [the upper normal limit of LDL–C level
according to our laboratory reference values]), the control
and hypertensive groups were further divided, resulting in
four subgroups (1) healthy controls, free of hypertension
or hyperlipidemia (CON; n ¼ 44; mean age  SEM,
42.5  1.36 years; male/female ratio, 1); (2) normotensive
subjects with elevated LDL–C levels (LDL; n ¼ 41; mean
age  SEM, 44.71  1.38 years; male/female ratio, 1.28);
(3) hypertensive patients with normal LDL–C levels (HT;
n ¼ 49; mean age  SEM; 41.67  1.47 years; male/female
ratio, 0.75); and (4) hypertensive patients with elevated
LDL–C levels (HT þ LDL; n ¼ 23; mean age  SEM,
47.70  1.83 years; male/female ratio, 1.56).MeasurementsThe following examinations were performed in all groups:
BP measurement, laboratory analysis, IMT measurement of
the common carotid arteries (CCAs), assessment of arterial
stiffness parameters, and neuropsychological testing.
BP Measurement
Primary diagnosis of hypertension was made by family
doctors and internists based on international guidelines.13
During our study protocol, office measurements of systolic,
diastolic, and mean arterial BPs served the purpose of data
collection. To this end, we applied an arteriograph medical
device (TensioClinic Arteriograph, TL1; TensioMed Ltd,
Hungary), which uses a standard oscillometric technique
to determine BP values in mm Hg. Measurements were per-
formed in supine position using a cuff placed on the resting
right arm with its lower edge located w25 mm above the
elbow and the air outlet directly above the brachial artery.
Laboratory Analysis
Fasting blood sampleswere taken for serumglucose, lipids,
and kidney function. The measured parameters were part of
the routine examination performed by theDepartment of Lab-
oratory Medicine, University of Debrecen. Quality assurance
of the laboratory was based on daily internal control and also
on participation in external quality control programs.
IMT Measurement
High-resolution B-mode carotid ultrasonography was per-
formed using a 7.5 MHz SonoSite MicroMaxx ultrasound19 May 2014  6:12 pm  ce





















































































300machine (SonoSite Inc, Bothell, WA, USA). Patients were
examined in supine position with the head turned 45 away
from the side being scanned. Measurements were performed
in plaque free regions on the far wall of both CCAsw1-cm
proximal to the carotid bulb. IMTwas defined as the distance
between the luminal endothelial interface and the junction
between the media and the adventitia. On examination,
R waves–triggered longitudinal B-mode images were re-
corded, saved, and stored for later offline analysis. Six mea-
surements per vessel were taken on both sides, and IMT data
of the two CCAs were averaged.
Arterial Stiffness
Measurements were performed with a validated, com-
puterized portable device (TensioClinic Arteriograph,
TL1).14,15 Pulse wave velocity (PWV, in m/s) and brachial
augmentation index (AIx, in %) were determined by
analyzing the oscillometric pressure curves registered on
the upper arm.16
Neuropsychological Examination
All participants completed a 1-hour (10 minutes) neu-
ropsychological test series assessing reaction time, mem-
ory, attention, executive function, psychomotor speed,
visual-spatial ability, anxiety, and depression.17 The applied
tests, previously used by several authors,18–32 can reveal
such minor alterations of the cognitive function, which
are not necessarily evident during everyday activity. All
























325Vascular and neuropsychological parameters (outcomes)
were described using standard statistics and compared
between groups with no adjustment using parametric or
nonparametric tests as appropriate for distributional charac-
teristics. Associations between factors and outcomes were
assessed using multiple linear regression adjusted for age,
sex, smoking status (all models), level of education (neuro-
psychological outcomes only; patients with college and/or
university degrees qualified for the category of higher edu-
cation, patients with a maximum of 12 years of education
[primary school or primary and secondary schools] quali-
fied for lower education category), mean arterial pressure
(MAP; unless BP was an explanatory or outcome variable),
and serum LDL–C level (unless lipid level was an explan-
atory or outcome variable). Effects of categorical factors
were expressed as expected values of between group differ-
ences with 95% confidence intervals and P values. Effects
of continuous variables were calculated for a single unit
increase and expressed similarly. Interactions between
hypertension and hyperlipidemia, and between hyperten-
sion and level of education were evaluated for potential
improvement of model fit.FLA 5.2.0 DTD  JASH508_proof ResultsClinical DataClinical data are presented in Table 1. None of the
patients had chronic kidney disease or diabetes. There
was no difference between the groups regarding gender,
smoking habit, fasting blood glucose, and creatinine levels.
In the hypertensive group, 29.2% of patients declared to be
an active or former smoker, whereas in the normotensive
group, this ratio was 21.2%. Among hypertensive patients,
44.4% declared moderate level alcohol consumption, 5.5%
admitted regular alcohol intake, whereas 48.6% were absti-
nent to alcohol. These ratios in the normotensive group
were 60%, 11.7%, and 24.7%, respectively.Intima-media ThicknessDespite IMT being in the normal range in all four groups,
during unadjusted comparison IMTwas significantly higher
in the HT group compared with CON (0.60  0.01 vs.
0.53  0.01 mm; P ¼ .0005) or LDL groups (0.60  0.01
vs. 0.55 0.01mm;P¼ .0142). A further increase of border-
line significance in the IMT value was found when hyperten-
sionwas associatedwith elevated LDL–C levels (0.60 0.01
vs. 0.67  0.03 mm for HT and HT þ LDL, respectively;
P ¼ .0505; Figure 1A). Adjusted comparison of subjects
with hyperlipidemia (LDL, HTþ LDL) to subjects with nor-
molipidemia (CON,HT) revealed no significant difference in
IMT values. However, when performing subgroup compari-
son between hypertensive (HT, HT þ LDL) and normoten-
sive subjects (CON, LDL) using multiple regression,
the difference in the IMT values remained significant
(0.62  0.01 vs. 0.54  0.01 mm; P < .0001). Furthermore,
during the analysis of the adjusted effect of MAP, we found a
significant increase of 0.0019 mm in the expected IMT value
for each mm Hg increase in MAP (P ¼ .0038).Stiffness ParametersRaw Qcomparisons revealed a significantly increased AIx
value in the HT and LDL groups compared to CON
(30.37  3.39 vs. 15.50  4.85%; P ¼ .0284 or
18.36  4.36%; P ¼ .0311, respectively). Hyperlipidemia
coexisting with hypertension further increased AIx values,
thus comparison between the HT þ LDL and CON groups
resulted in an even greater difference (10.43  5.97 vs.
30.37  3.39%; P ¼ .0026; Figure 1B). When subjects
with hyperlipidemia versus normolipidemia were compared
using multiple regression, no significant difference was
found in the AIx values. In contrast, adjusted comparison
of hypertensive and normotensive participants revealed a sig-
nificant difference (14.39  3.61 vs. 24.12  2.76%,
respectively; P ¼ .0023).
Value of PWV was the lowest in CON, whereas highest in
the HTþ LDL group. PWV values of those participants with19 May 2014  6:12 pm  ce
Table 1
Clinical data of the participants
Variable CON (N ¼ 44) LDL (N ¼ 41) HT (N ¼ 49) HT þ LDL
(N ¼ 23)
P Value
Age (years) 42.5  1.36a 44.71  1.38 41.67  1.47b 47.70  1.83a,b a.0271, b.0181
Male/female (%) 50/50 56.1/43.9 42.9/57.1 60.9/39.1 NS
BMI (kg/m2) 24.49  0.60a,b,c 26.23  0.57a 26.90  0.55b 27.95  0.71c a.0396, b.0039, c.0007
Non/active or former
smoker
35/9 31/9 32/17 19/4 NS
Higher education
(þ/)
31/13a,b 29/12c,d 20/29a,c 8/15b,d a.006, b.009, c.006,d.008
MAP (mm Hg) 92.21  1.48a,b 93.48  1.29c,d 102.40  1.69a,c,e 108.36  2.35b,d,e a,b,d< .0001, c.0001, e.047
SBP (mm Hg) 126.60  2.01a,b 126.5  2.13c,d 138.81  2.34a,c 143.82  3.14b,d a,c.0002,b,d< .0001,
DBP (mm Hg) 75.09  1.41a,b 76.98  1.32c,d 84.17  1.58a,c,e 90.64  2.16b,d,e a.0001,b,d< .0001,c.001, e.0215
FBG (mmol/L) 5.05  0.10 5.25  0.08 5.10  0.08 5.33  0.12 NS
T–C (mmol/L) 4.77  0.09a,b 6.18  0.11a,c 4.78  0.11c,d 6.37  0.11b,d a,b,c,d< .0001
LDL–C (mmol/L) 2.68  0.07a,b 4.09  0.08a,c 2.69  0.08c,d 4.18  0.10b,d a,b,c,d< .0001
HDL–C (mmol/L) 1.62  0.07a 1.48  0.07 1.48  0.09a 1.56  0.10 a.0237
TG (mmol/L) 1.04  0.09a,b,c 1.52  0.11a,d 1.38  0.13b,d 1.59  0.17c a<.0001, b.0318, c.0004,d.0356
Creatinine (mmol/L) 70.98  2.08 68.55  2.52 67.98  2.10 72.77  3.61 NS
BMI, body mass index; CON, healthy controls; FBG, fasting blood glucose; HDL–C, high-density lipoprotein cholesterol; HT, hyper-
tensive patients; HT þ LDL, hypertensive patients with elevated low-density lipoprotein cholesterol level; LDL, subjects with elevated low-
density lipoprotein cholesterol level; LDL–C, low-density lipoprotein cholesterol; MAP, mean arterial blood pressure; NS, not significant;
SBP, systolic blood pressure; T–C, total cholesterol; TG, triglyceride.
Data are presented as means  standard error of the mean, percentage (for male/female ratio) or as absolute numbers (for smoking status
and education).
a, b, c, d, and e indicate affiliated group comparisons of corresponding P values.







































































































428only one risk factor were intermediate. Unadjusted estima-
tions showed a significant difference between PWV values
of CON and HT groups (8.01  0.21 vs. 9.64  0.40 m/s,
respectively; P¼ .0029). Likewise, PWV values were further
increased in the group of patients with both risk factors,
therefore the differences between HT þ LDL and CON or
LDL groups were also significant (10.02  0.35 vs.
8.01  0.21 m/s; P < .0001 or 8.79  0.41 m/s; P ¼ .0019,
respectively; Figure 1C). Adjusted comparison of subjects
with hyperlipidemia versus normolipidemia resulted in
no significant difference. However, when hypertensive and
normotensive participants were compared, significantly
higher values were observed in association with hypertension
(9.74  0.28 vs. 8.46  0.23 m/s; P < .0001).
While analyzing the adjusted effect of LDL–C level on
arterial stiffness parameters, we found no significant effect.
However, MAP-adjusted effect on arterial stiffness parame-
ters showed a significant elevation of 0.50% in the expected
value of AIx (P ¼ .0004) and a significant elevation of
0.058 m/s in the expected value of PWV (P < .0001) for








Detailed presentation of the applied tests and group com-
parisons are shown in Table 2. Adjusted comparison ofFLA 5.2.0 DTD  JASH508_proof normotensive versus hypertensive participants resulted
in significant differences when assessing choice reaction
time or memory and attention with the digit span test
(P ¼ .0405 and P ¼ .0002 for choice reaction time and digit
span test, respectively; data not shown). Sum of standardized
test scores (SSTS), which comprises the results of all neuro-
psychological tests (except questionnaires assessing anxiety
and depression), revealed a tendency as follows: subjects
with no risk factor reached the highest, whereas patients
with both risk factors the lowest scores. For the two other
groups intermediate values were observed. During unad-
justed comparison significant difference in SSTS could be
detected between the CON and HT or HT þ LDL groups
(1.97  0.59 vs. 0.02  0.64; P ¼ .0285 or 0.51  1.13;
P ¼ .0413, respectively; Figure 2). Although the adjusted
between-groups comparison revealed a strong, but nonsignif-
icant tendency for hypertensive patients to reach lower scores
compared with normotensive subjects (0.27  0.59 vs.
1.37  0.46, respectively; P ¼ .1015), the assessment of
the adjusted effect of MAP on SSTS resulted in a significant
reduction of 0.1169 in the expected score for each mm Hg
increase in MAP (P < .0001).
Anxiety and Depression
Although Spielberger state anxiety scores revealed no sig-
nificant differences between the groups, unadjusted compar-
ison of Spielberger trait inventory revealed significantly19 May 2014  6:12 pm  ce
Figure 1. Unadjusted comparisons of morphologic and func-
tional parameters of the vascular wall in the four groups. (A)
Intima-media thickness values (in mm). (B) Augmentation Index
values (in %). (C) Pulse wave velocity values (in m/s). Columns
showmeans standard error of themean. CON, healthy controls;
LDL, subjects with elevated low-density lipoprotein cholesterol
level; HT, hypertensive patients; HT þ LDL, hypertensive
patients with elevated low-density lipoprotein cholesterol level;
n: number of subjects.
5K.R. Kovacs et al. / Journal of the American Society of Hypertension -(-) (2014) 1–11














































































































545higher scores in the HT group compared with CON
(39.56  1.27 vs. 33.42  1.10; P ¼ .0005). Moreover, a
further increase of scores was found, when hypertension
associated with elevated LDL–C levels (41.38  2.03 vs.
33.42  1.10; P ¼ .0009 or 37.11  1.62; P ¼ .0456 for
HTþ LDL and CON or LDL, respectively).When analyzing
the difference between hypertensive and normotensive par-
ticipants with multiple regression, significantly higher Spiel-
berger trait anxiety scores were observed in hypertensive
patients (39.68  1.04 vs. 35.15  0.97; P ¼ .0014).
Although patients with both risk factors reached the highest
score during Beck depression inventory, there was no signif-
icant difference between the groups either in unadjusted, or
in adjusted models.
Adjusted effect of MAP and that of LDL–C on the
different studied parameters are summarized in Table 3.
Discussion
This study revealed that subtle changes of vascular wall
properties and that of cognitive function are already present
in recently diagnosed hypertensive patients. Analysis of the
adjusted effect of MAP shed light on the gradual elevation
of IMT, AIx, and PWV values with increasing BP, which
certifies the causative role of hypertension in these early
morphologic and functional alterations of the vasculature.
Regarding cognitive performance, there was a clear ten-
dency as follows: healthy subjects reached the highest,
whereas patients with both risk factors the lowest scores,
when SSTS was evaluated. The level of anxiety also tended
to be higher in the presence of risk factors. Although hyper-
lipidemia per se did not result in significant worsening of
the previously mentioned parameters, when it was associ-
ated with hypertension, more pronounced impairments
could be observed.
Pall et al.33 previously demonstrated that IMT values of
the CCAwere higher in hypertensive adolescents compared
with healthy controls, suggestive of ongoing target organ
damage in young patients with short-lasting hypertension.
Accordingly, we also observed significantly higher IMT
values in early-stage hypertensive adults in their mid-40s
when compared with controls. In addition, Amer et al.34
recently found that hypertension duration was positively
correlated with IMT among senescent hypertensive pa-
tients. These findings indicate that hypertension leads to
higher IMT values of the arterial wall in all ages.
In our study population, the increasing number of risk fac-
tors induced more explicit changes. When analyzing LDL–
C-adjusted effects, we found no significant differences
between the groups. This observation suggests that although
hyperlipidemia is definitely a contributing factor to the dete-
rioration of the vascular system, per se it may not yet result
in detectable changes at this early stage. In contrast with our
results, when Vladimirova-Kitova et al.35 evaluated IMT
in asymptomatic, nontreated, severe hypercholesterolemic19 May 2014  6:12 pm  ce
Table 2
Group comparisons on neuropsychological test performance
Neurospychological Test Function CON (n ¼ 43) LDL (n ¼ 39) HT (n ¼ 46) HT þ LDL
(n ¼ 22)
P Value
Choice Reaction Time (s) Reaction time 0.52  0.01a,b 0.54  0.01 0.56  0.01a 0.56  0.02b a.0105, b.011
Selective Reaction
Time (s)
Reaction time 0.62  0.01 0.65  0.01 0.65  0.02 0.64  0.03 NS
RAVLT score Memory 13.19  0.38 13.05  0.42 12.28  0.44 11.48  0.86 NS
First Recognition score Memory 12.55  0.30a 11.69  0.32a 11.67  0.33 11.82  0.59 a.0117
Pieron Test (%) Attention and
vigilance





32.25  2.11 33.11  2.49 27.51  1.67a 35.95  3.00a a.0153
Digit Span Test score* Memory, attention
and vigilance
11.70  0.31a,b 11.97  0.42c,d 10.07  0.30a,c 10  0.54b,d a.0006, b.0011,
c.0003, d.0034
Block Design Test (s) Visuo-spatial and
motor skills
26.07  0.53 25.28  0.53 25.67  0.58 24.9  0.83 NS
Digit Symbol Test score General processing
speed
52.77  1.50a 49.63  1.43 50.60  1.34b 44.33  2.69a,b a.0051, b.0238
Spielberger State Anxiety
score
Anxiety 39.47  1.58 39.55  1.86 42.09  1.31 42.36  2.16 NS
Spielberger Trait Anxiety
score
Anxiety 33.42  1.10a,b 37.11  1.62c 39.56  1.27a 41.38  2.03b,c a.0005, b.0009,
c.0456
Beck Depression score Depression 5.14  0.68 5.32  1.02 5.89  0.96 7.09  1.46 NS
CON, healthy controls; HT, hypertensive patients; HT þ LDL, hypertensive patients with elevated low-density lipoprotein cholesterol
level; LDL, subjects with elevated low-density lipoprotein cholesterol level; RAVLT Q8, Rey Auditory Verbal Learning test; s, second.
Data are presented as means  standard error of the mean.
a, b, c, and d indicate affiliated group comparisons of corresponding P values.
* Digit span test score comprises forward and backward recalls as well.























































































632subjects, they found that these individuals were at a high risk
of having increased IMT, especially if endothelial dysfunc-
tion was also present. The discrepancy between theseFigure 2. Unadjusted comparisons of the sum of standardized
test scores in the four groups. Columns show means  standard
error of the mean. CON, healthy controls; LDL, subjects with
elevated low-density lipoprotein cholesterol level; HT, hyperten-
sive patients; HT þ LDL, hypertensive patients with elevated
low-density lipoprotein cholesterol level; n: number of subjects.























655observations may originate from a difference in lipid levels,
although our patients had only moderately high levels
of LDL–C with an average of 4.13  0.06 mmol/L
(mean  SEM), the population studied by Vladimirova-
Kitova et al.35 had severe hyperlipidemia. In another study,
Li et al.36 observed that over a mean of 10.7 years follow-up,
patients with normal BP (<140/90 mm Hg) but with carotid
artery atherosclerosis (defined as mean IMT0.81 mm and/
or presence of a plaque [IMT>1.2 mm]) had a 3-fold higher
risk of ischemic stroke compared with those with normal
carotid arteries. This difference remained significant even
when risk was adjusted for age, sex, BP, cholesterol, fasting
glucose, and smoking.36 These observations emphasize the
importance of IMT monitoring, as higher values may draw
attention to an increasing stroke risk.
Regarding arterial stiffness, N€urnberger et al.37 previ-
ously observed that AIx was correlated with age, diastolic
BP, heart rate, height, and gender in a population that was
free of any atherosclerotic disease. Similarly, in subjects
with atherosclerosis, all these parameters were correlated
with AIx, with the exception of age.37 Accordingly, in our
study, we found higher AIx values in hypertensive subjects
after adjustment for parameters such as age, gender, serum
LDL–C level, and smoking status. At the moment, data
regarding the relationship between serum lipid levels and
arterial stiffness are controversial. Wilkinson et al.38 found19 May 2014  6:12 pm  ce
Table 3
Adjusted Q9effect of mean arterial pressure and that of LDL cholesterol level on variables
Variable Adjusted Effect of Mean Arterial Pressure
(Contrast, þ1 mm Hg)
Adjusted Effect of LDL Cholesterol
(Contrast, þ1 mmol/L)
Effect 95% CI P Value Effect 95% CI P Value
Intima-media thickness (mm) 0.0019 0.0006 to 0.0032 .0038 0.0078 0.0094 to 0.0249 .3715
Augmentation index (%) 0.5047 0.2302 to 0.7793 .0004 3.0808 0.6266 to 6.7882 .1027
Pulse wave velocity (m/s) 0.0580 0.0308 to 0.0853 <.0001 0.1356 0.2321 to 0.5033 .4673
Choice reaction time (s) 0.0018 0.0008 to 0.0029 .0008 0.0046 0.0086 to 0.0178 .4931
Selective reaction time (s) 0.0009 0.0007 to 0.0025 .2687 0.0037 0.0167 to 0.0241 .7192
RAVLT score 0.0537 0.0953 to 0.0120 .012 0.1320 0.3917 to 0.6558 .6189
First recognition score 0.0401 0.0732 to 0.0070 .0181 0.0397 0.3781 to 0.4574 .8514
Pieron test (%) 0.0985 0.2314 to 0.0343 .1447 0.0157 1.6380 to 1.6696 .985
Trail making test (s) 0.0739 0.1305 to 0.2783 .4756 1.7883 0.7541 to 4.3306 .1665
Digit span test score* 0.0727 0.1052 to 0.0402 <.0001 0.3781 0.0315 to 0.7877 .0701
Block design test (s) 0.0434 0.0946 to 0.0079 .0966 0.4259 1.0733 to 0.2215 .1955
Digit symbol test score 0.2290 0.3620 to 0.0960 .0009 0.6031 2.2576 to 1.0515 .4721
SSTS 0.1169 0.1715 to 0.0623 <.0001 0.1351 0.8147 to 0.5446 .6947
Spielberger state anxiety score 0.0724 0.0841 to 0.2290 .3619 0.5793 2.5609 to 1.4023 .5641
Spielberger trait anxiety score 0.0823 0.0579 to 0.2224 .2477 0.7739 1.0001 to 2.5478 .3898
Beck depression score 0.0294 0.0619 to 0.1208 .5248 0.6410 0.5295 to 1.8116 .2807
LDL, low-density lipoprotein; RAVLT, Rey Auditory Verbal Learning test; SSTS, sum of standardized test scores; s, second.
*Digit Span test score comprises forward and backward recalls as well.














































































































765that patients with hypercholesterolemia had stiffer blood
vessels than matched controls, despite their similar periph-
eral BP values. Although their study showed that stiffness
was independently correlated with LDL,38 N€urnberger
et al.37 found no significant association between cholesterol
levels and AIx. In agreement with the latter investigator
group, we could not demonstrate any significant effect of
serum LDL–C level on AIx in our study.
Safar et al.39 previously stated that increased aortic PWV
is a strong and independent predictor of cardiovascular risk,
regardless of whether this mechanical factor plays a causa-
tive role or merely serves as a marker of vascular disease
already present. It has been shown in a recent study that
PWVat any age is related linearly to systolic, whereas sym-
metrically to any BP level, and is proportional to the square
of age. Moreover, after correction for squared age and BP,
PWV was not significantly influenced by smoking or lipid
status, and gender differences were also negligible.40 Like-
wise, in our study, PWV was significantly higher in hyper-
tensive subjects compared with normotensive ones during
multiple regression analysis; however, there was no signif-
icant difference between PWV values of normolipidmic
versus hyperlipidemic subjects. Based on these observa-
tions it is likely that the hypertension- and aging-related
vascular stiffness is independent of hyperlipidemia. Previ-
ous studies suggest that stiffening of the arterial wall in
hypertensive and/or senescent individuals may derive
from mechanisms such as fibrosis or calcification induced
vascular changes.41–43
Of note, numerous investigations justified that changes
of IMT and arterial stiffness parameters in hypertensiveFLA 5.2.0 DTD  JASH508_proof patients can be improved by various antihypertensive ther-
apies.44–47
So far, the relationship between cognitive function and
hypertension has been examined by several authors. Debette
et al.48 evaluated the association of vascular risk factor expo-
sure in midlife with cognitive decline in participants without
dementia from the prospective Framingham Offspring
Cohort Study. They found that hypertension in midlife was
associated with a worsening executive function.48 Accord-
ingly, Knecht et al.27 found that systolic BP explained up
to 11% of the variance in cognitive performance in nonde-
mented groups of individuals in midlife age, suggesting
that in this population hypertension may account for one-
tenth of cognitive impairment and thus for an increased
risk for dementia. Another study performed by Vicario
et al.19 demonstrated that cognitive impairment of hyperten-
sive patients is present in areas such as attention, memory,
and executive function.19 While evaluating middle-aged,
never-treated hypertensive patients, Sierra et al.49 first
described that the presence of silent cerebral white matter
lesions is associated with a mild decline in basic attention.
The previously mentioned findings are in accordance with
our results, as our hypertensive patients reached lower scores
particularly in tests evaluating memory and attention. In
general, we could not demonstrate any significant effect of
adjusted LDL–C on cognitive function. Nonetheless, when
calculating the SSTS, substantially lower scores could be
observed in hypertensive patients, which became even
more explicit when both risk factors were present. After
all, these early and subtle changes of neuropsychological
parameters cannot be noticed during the everyday life of an19 May 2014  6:12 pm  ce














































































































875individual. However, they indicate a disturbed cognitive
performance in this early stage of hypertension. Several
hypotheses have been previously proposed to provide
plausible explanation for the pathomechanism of neuropsy-
chological deterioration in the setting of hypertension;
structural vascular changes leading to extracellular edema,
disruption of the blood-brain barrier, chronic cortical deaf-
ferentation resulting in vessel obstruction leading to
ischemia,50 insufficient cerebral blood flow,51,52 disturbed
cerebral metabolism, autoregulation or neurochemistry,
enhanced cardiovascular and neuroendocrine reactivity,52,53
anxiety,54 and so forth. Likewise, the pathophysiology of
hyperlipidemia-associated cognitive decline has also been
thoroughly studied (b-amyloid generation, t-hyperphos-
phorylation, inflammation in the brain,55,56 etc.), but the
exact links between cognitive impairment and these two
important cerebrovascular and cardiovascular risk factors
are yet to be clarified. Importantly, the early cognitive deficit
of young hypertensive individuals can be reversed with an
appropriate antihypertensive therapy, as suggested by previ-
ous findings.24,57–59
The association between high BP and anxiety is supported
by a large number of case–control studies, which compared
either psychological symptoms in hypertensive and control
subjects, or BP in patients with a variety of psychiatric disor-
ders and controls.60When examining anxiety disorder, Vetere
et al.61 found a higher prevalence in hypertensive individuals
compared with controls. Our hypertensive patients also
reached higher scores on anxiety inventories. Recently it
was proposed that anxiety could play an important role in
hypertension development through altered autonomic control
of the heart.62 In another study performed by Paterniti et al.63
anxiety was independently-, whereas depression was not,
associated with an increased risk for high BP. Although their
findings did not permit the establishment of a causal relation-
ship between anxiety andBP, it was suggested that behavioral
patterns of anxious patients, such as lifestyle, diets, drinking,
smoking, or other habits might play a role as risk factors for
high BP development.63 After all, it needs further investiga-
tions to elucidate whether patients with hypertension are
more susceptible to anxiety or rather subjects with anxiety
tend to develop hypertension over time.
Conclusions
Our results provide insight into the early vascular alter-
ations and cognitive disturbance induced by newly diagnosed
hypertension and hyperlipidemia. Subclinical changes pro-
duced by these two risk factors were investigated in selected
patient groups in a comprehensive manner. We demonstrated
that subtle changes in the morphologic and functional char-
acteristics of the arterial wall and cognitive performance
could already be detected in recently diagnosed hypertensive
patients. These fine alterations may be the first signs of the
devastating complications of long-standing hypertension.FLA 5.2.0 DTD  JASH508_proof Of note, when hyperlipidemia was associated with hyperten-
sion, a more pronounced deterioration of the vasculature
could be detected, which underscores the importance of
prompt recognition and appropriate treatment of both risk
factors. These results can particularly be exploited during
the everyday clinical practice, where borderline changes of
BP or LDL–C levels are often neglected. Our study also
points out that monitoring of individuals for high BP and
serum lipid levels is essential not only in the apparently ill,
but also in the seemingly healthy, asymptomatic subjects as
well. Education of these individuals facilitates an early alert
for their already existing risk factors, and thus, can not only
contribute to a successful treatment, but may also prevent
further impairments. In the future, screening evaluation
studies may be necessary to assess economical aspects of a
systematic, widespread screening of the population for these
existing risk factors.Acknowledgments
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